Insider Monkey
Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA)
📈
AI Sentiment
Highly Positive
9/10
- Home
- CNTA
as of 02-18-2026 3:38pm EST
$25.11
+$0.17
+0.68%
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | US |
| Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 3.5B | IPO Year: | 2021 |
| Target Price: | $38.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.98 | EPS Growth: | -31.21 |
| 52 Week Low/High: | $9.60 - $30.58 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -25.59 | Index: | N/A |
| Free Cash Flow: | -142089000.0 | FCF Growth: | N/A |
AI-Powered CNTA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.39%
70.39%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)
HUSSAIN IQBAL J
Sell
Chief Legal Officer
CNTA Feb 2, 2026
Avg Cost/Share
$25.15
Shares
38,951
Total Value
$979,656.60
Owned After
57,645
SEC Form 4
HUSSAIN IQBAL J
Sell
Chief Legal Officer
CNTA Jan 30, 2026
Avg Cost/Share
$25.01
Shares
1,010
Total Value
$25,261.01
Owned After
57,645
SEC Form 4
Accardi Mario Alberto
Sell
President, Orexin Program
CNTA Dec 9, 2025
Avg Cost/Share
$28.95
Shares
10,000
Total Value
$288,288.91
Owned After
181,369
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| HUSSAIN IQBAL J | CNTA | Chief Legal Officer | Feb 2, 2026 | Sell | $25.15 | 38,951 | $979,656.60 | 57,645 | |
| HUSSAIN IQBAL J | CNTA | Chief Legal Officer | Jan 30, 2026 | Sell | $25.01 | 1,010 | $25,261.01 | 57,645 | |
| Accardi Mario Alberto | CNTA | President, Orexin Program | Dec 9, 2025 | Sell | $28.95 | 10,000 | $288,288.91 | 181,369 |
Latest Centessa Pharmaceuticals plc News
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
Simply Wall St.
Centessa Pharmaceuticals (CNTA) Valuation Check After Recent Share Price Strength
📊
AI Sentiment
Positive
6/10
MarketBeat
Centessa Pharmaceuticals CEO Teases “Transformational” 2026 as ORX750 Nears Registrational Trials
📈
AI Sentiment
Highly Positive
9/10
Compare CNTA vs Leading Stocks
See how CNTA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.